One case of thrombocytopenia induced by sodium valproate sustained release tablets and literature review
Qiang Xiong and Ying Chan Wang
More than a century ago, American chemist Beverly S. Burton synthesis of sodium valproate (VPA). At
present, sodium valproate is widely used in clinic as an effective antiepileptic and emotional stability
drug. Its mechanism of anti-epileptic and emotional stability is not fully understood. Studies have
shown that VAP is obtained by changing the metabolism of GABA. Recently, several studies have
further demonstrated the pharmacodynamic properties of the compound, including direct effects
on voltage-gated sodium channels or disruption of the sodium channel membrane environment
[2].Sodium valproate sustained-release tablets were used in the treatment of schizophrenia. One
case of thrombocytopenia was found. After 6 days of withdrawal, platelet count (PLT) returned to
normal. Considering the wide application of sodium valproate and the long-term medication of
most patients with chronic diseases, spontaneous bleeding may occur when the platelet count is
reduced seriously, and life may be endangered when it is serious, the author reviewed the relevant
literature and reported it.
